For example, first-generation EGFR-TKIs erlotinib (Minna and Dowell, 2005) and gefitinib (Cohen et al., 2003) showed an encouraging response rate to NSCLC with EGFR mutations (exon 19 deletions and L858R point mutations). Here, EGFR is linked to non-small cell lung carcinoma.